drugset

drugset / Trial / NCT02637960

Efficacy Study of Fedovapagon for Nocturia in Men With Benign Prostatic Hyperplasia (BPH)

NCT02637960 ↗

Phase 2/3 Completed 432 enrolled Vantia Ltd

RandomizedParallel-groupTriple-blindTreatment

Summary

This study will investigate the efficacy and safety of fedovapagon in the treatment of nocturia in men with BPH.

Timeline

Start: 2016-03
Primary completion: 2017-07
Completion: 2017-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Fedovapagon	Unknown	2 mg	—

Indications